Idexx Laboratories, Inc. (IDXX)

$477.79

-0.45

(-0.09%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Idexx Laboratories, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 943.63M → 901.60M (in $), with an average decrease of 2.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 224.23M → 194.52M (in $), with an average decrease of 6.9% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 12.9%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 16.0%

Performance

  • $475.84
    $483.10
    $477.79
    downward going graph

    0.41%

    Downside

    Day's Volatility :1.5%

    Upside

    1.1%

    downward going graph
  • $372.50
    $583.39
    $477.79
    downward going graph

    22.04%

    Downside

    52 Weeks Volatility :36.15%

    Upside

    18.1%

    downward going graph

Returns

PeriodIdexx Laboratories, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-8.96%
-0.7%
4.2%
6 Months
12.44%
6.6%
17.8%
1 Year
-0.8%
3.7%
29.0%
3 Years
-9.52%
14.0%
11.6%

Highlights

Market Capitalization
40.7B
Book Value
$17.88
Earnings Per Share (EPS)
10.04
PE Ratio
48.76
PEG Ratio
4.75
Wall Street Target Price
604.62
Profit Margin
23.08%
Operating Margin TTM
27.21%
Return On Assets TTM
22.83%
Return On Equity TTM
80.74%
Revenue TTM
3.7B
Revenue Per Share TTM
44.07
Quarterly Revenue Growth YOY
8.799999999999999%
Gross Profit TTM
2.0B
EBITDA
1.2B
Diluted Eps TTM
10.04
Quarterly Earnings Growth YOY
0.12
EPS Estimate Current Year
11.13
EPS Estimate Next Year
12.7
EPS Estimate Current Quarter
2.12
EPS Estimate Next Quarter
2.7

Analyst Recommendation

Buy
    64%Buy
    35%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Idexx Laboratories, Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
13
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.55%

Current $477.79
Target $604.62

Company Financials

FY18Y/Y Change
Revenue
2.2B
↑ 12.4%
Net Income
377.0M
↑ 43.28%
Net Profit Margin
17.04%
↑ 3.68%
FY19Y/Y Change
Revenue
2.4B
↑ 8.75%
Net Income
427.7M
↑ 13.44%
Net Profit Margin
17.77%
↑ 0.73%
FY20Y/Y Change
Revenue
2.7B
↑ 12.45%
Net Income
581.8M
↑ 36.02%
Net Profit Margin
21.49%
↑ 3.72%
FY21Y/Y Change
Revenue
3.2B
↑ 18.79%
Net Income
744.8M
↑ 28.03%
Net Profit Margin
23.17%
↑ 1.68%
FY22Y/Y Change
Revenue
3.4B
↑ 4.73%
Net Income
679.1M
↓ 8.83%
Net Profit Margin
20.17%
↓ 3.0%
FY23Y/Y Change
Revenue
3.7B
↑ 8.72%
Net Income
845.0M
↑ 24.44%
Net Profit Margin
23.08%
↑ 2.91%
Q3 FY22Q/Q Change
Revenue
841.7M
↓ 2.19%
Net Income
180.9M
↑ 37.1%
Net Profit Margin
21.5%
↑ 6.16%
Q4 FY22Q/Q Change
Revenue
828.6M
↓ 1.56%
Net Income
172.2M
↓ 4.83%
Net Profit Margin
20.78%
↓ 0.72%
Q1 FY23Q/Q Change
Revenue
900.2M
↑ 8.64%
Net Income
214.1M
↑ 24.3%
Net Profit Margin
23.78%
↑ 3.0%
Q2 FY23Q/Q Change
Revenue
943.6M
↑ 4.83%
Net Income
224.2M
↑ 4.76%
Net Profit Margin
23.76%
↓ 0.02%
Q3 FY23Q/Q Change
Revenue
915.5M
↓ 2.98%
Net Income
212.2M
↓ 5.35%
Net Profit Margin
23.18%
↓ 0.58%
Q4 FY23Q/Q Change
Revenue
901.6M
↓ 1.52%
Net Income
194.5M
↓ 8.34%
Net Profit Margin
21.58%
↓ 1.6%
FY18Y/Y Change
Total Assets
1.5B
↓ 10.28%
Total Liabilities
1.5B
↓ 12.49%
FY19Y/Y Change
Total Assets
1.8B
↑ 19.2%
Total Liabilities
1.7B
↑ 6.99%
FY20Y/Y Change
Total Assets
2.3B
↑ 25.22%
Total Liabilities
1.7B
↑ 0.43%
FY21Y/Y Change
Total Assets
2.4B
↑ 6.22%
Total Liabilities
1.7B
↑ 5.14%
FY22Y/Y Change
Total Assets
2.7B
↑ 12.7%
Total Liabilities
2.1B
↑ 22.37%
FY23Y/Y Change
Total Assets
3.3B
↑ 18.68%
Total Liabilities
1.8B
↓ 16.96%
Q3 FY22Q/Q Change
Total Assets
2.6B
↑ 1.26%
Total Liabilities
2.2B
↑ 0.65%
Q4 FY22Q/Q Change
Total Assets
2.7B
↑ 4.04%
Total Liabilities
2.1B
↓ 1.2%
Q1 FY23Q/Q Change
Total Assets
2.8B
↑ 2.24%
Total Liabilities
2.0B
↓ 7.99%
Q2 FY23Q/Q Change
Total Assets
2.9B
↑ 2.22%
Total Liabilities
1.8B
↓ 9.68%
Q3 FY23Q/Q Change
Total Assets
3.1B
↑ 7.51%
Total Liabilities
1.8B
↑ 0.68%
Q4 FY23Q/Q Change
Total Assets
3.3B
↑ 5.62%
Total Liabilities
1.8B
↓ 0.76%
FY18Y/Y Change
Operating Cash Flow
400.1M
↑ 7.18%
Investing Cash Flow
138.6M
↓ 199.94%
Financing Cash Flow
-597.8M
↑ 187.38%
FY19Y/Y Change
Operating Cash Flow
459.2M
↑ 14.77%
Investing Cash Flow
-205.5M
↓ 248.29%
Financing Cash Flow
-286.4M
↓ 52.09%
FY20Y/Y Change
Operating Cash Flow
648.1M
↑ 41.14%
Investing Cash Flow
-109.4M
↓ 46.78%
Financing Cash Flow
-248.4M
↓ 13.27%
FY21Y/Y Change
Operating Cash Flow
755.5M
↑ 16.59%
Investing Cash Flow
-293.0M
↑ 167.85%
Financing Cash Flow
-697.4M
↑ 180.74%
FY22Y/Y Change
Operating Cash Flow
543.0M
↓ 28.13%
Investing Cash Flow
-195.4M
↓ 33.32%
Financing Cash Flow
-370.9M
↓ 46.81%
Q3 FY22Q/Q Change
Operating Cash Flow
189.0M
↑ 187.02%
Investing Cash Flow
-49.2M
↓ 10.69%
Financing Cash Flow
-148.8M
↑ 61.93%
Q4 FY22Q/Q Change
Operating Cash Flow
173.4M
↓ 8.24%
Investing Cash Flow
-49.2M
↑ 0.07%
Financing Cash Flow
-116.7M
↓ 21.57%
Q1 FY23Q/Q Change
Operating Cash Flow
183.9M
↑ 6.05%
Investing Cash Flow
-39.5M
↓ 19.74%
Financing Cash Flow
-146.1M
↑ 25.16%
Q2 FY23Q/Q Change
Operating Cash Flow
200.3M
↑ 8.92%
Investing Cash Flow
-27.5M
↓ 30.48%
Financing Cash Flow
-151.0M
↑ 3.39%

Technicals Summary

Sell

Neutral

Buy

Idexx Laboratories, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • BlackRock Inc

    10.90%

  • Vanguard Group Inc

    10.09%

  • State Street Corporation

    4.55%

  • AllianceBernstein L.P.

    3.54%

  • Fundsmith LLP

    3.29%

  • BAMCO Inc

    2.77%

Company Information

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Organization
Idexx Laboratories, Inc.
Employees
11000
CEO
Mr. Jonathan J. Mazelsky
Industry
Health Technology

Discover More

FAQs